Therapeutic Aerosol Bioengineering of Targeted, Inhalable Microparticle Formulations to Treat Mycobacterium Tuberculosis (MTb)

Overview

Journal J Mater Sci Mater Med

Publisher Springer

Specialty Biomedical Engineering

Date 2011 Dec 21

PMID 22183789

Citations 3

Authors

C Lawlor

M P OSullivan

B Rice

P Dillon

P J Gallagher

S OLeary

S Shoyele

J Keane

S-A Cryan

Affiliations

Soon will be listed here.

Abstract

Therapeutic aerosol bioengineering (TAB) of Mycobacterium tuberculosis (MTb) therapies using inhalable microparticles offers a unique opportunity to target drugs to the site of infection in the alveolar macrophages, thereby increasing dosing in the lungs and limiting systemic exposure to often toxic drugs. Previous work by us used sophisticated, high content analysis to design the optimal poly(lactide-co-glycolic) acid (PLGA) microparticle for delivery of drugs to alveolar macrophages. Herein, we applied this technology to three different anti-MTb drugs. These formulations were then tested for encapsulation efficiency, drug-release, in vitro killing against MTb and aerosol performance. Methods for encapsulating each of the drugs in the PLGA microparticles were successfully developed and found to be capable of controlling the release of the drug for up to 4 days. The efficacy of each of the encapsulated anti-MTb drugs was maintained and in some cases enhanced post-encapsulation. A method of processing these drug-loaded microparticles for inhalation using standard dry powder inhaler devices was successfully developed that enabled a very high respirable dose of the drug to be delivered from a simple dry powder inhaler device. Overall, TAB offers unique opportunities to more effectively treat MTb with many potential clinical and economic benefits resulting.

Citing Articles

A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.

Khadka P, Dummer J, Hill P, Katare R, Das S Drug Deliv Transl Res. 2022; 13(5):1246-1271.

PMID: 36131190 PMC: 9491662. DOI: 10.1007/s13346-022-01238-y.

Treatment of Mycobacterium tuberculosis-Infected Macrophages with Poly(Lactic-Co-Glycolic Acid) Microparticles Drives NFκB and Autophagy Dependent Bacillary Killing.

Lawlor C, OConnor G, OLeary S, Gallagher P, Cryan S, Keane J PLoS One. 2016; 11(2):e0149167.

PMID: 26894562 PMC: 4760758. DOI: 10.1371/journal.pone.0149167.

Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis.

Wu J, Zuo Y, Hu Y, Wang J, Li J, Qiao B Drug Des Devel Ther. 2015; 9:1359-66.

PMID: 25834394 PMC: 4357616. DOI: 10.2147/DDDT.S78407.

References

Pilcer G, Amighi K . Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010; 392(1-2):1-19. DOI: 10.1016/j.ijpharm.2010.03.017. View

Lawlor C, OSullivan M, Sivadas N, OLeary S, Gallagher P, Keane J . The application of high-content analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages. Mol Pharm. 2011; 8(4):1100-12. DOI: 10.1021/mp1004178. View

OHara P, Hickey A . Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000; 17(8):955-61. DOI: 10.1023/a:1007527204887. View

Dunbar C, Kataya A, Tiangbe T . Reducing bounce effects in the Andersen cascade impactor. Int J Pharm. 2005; 301(1-2):25-32. DOI: 10.1016/j.ijpharm.2005.04.039. View

Rabbani N, Seville P . The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release. 2005; 110(1):130-40. DOI: 10.1016/j.jconrel.2005.09.004. View

Srichana T, Martin G, Marriott C . Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci. 1998; 7(1):73-80. DOI: 10.1016/s0928-0987(98)00008-6. View

Daviskas E, Anderson S, Eberl S, Young I . Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J. 2007; 31(4):765-72. DOI: 10.1183/09031936.00119707. View

Muttil P, Wang C, Hickey A . Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2010; 26(11):2401-16. DOI: 10.1007/s11095-009-9957-4. View

Yadav A, Misra A . Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity. Antimicrob Agents Chemother. 2007; 51(10):3740-2. PMC: 2043254. DOI: 10.1128/AAC.00925-07. View

10.

Jensen D, Cun D, Maltesen M, Frokjaer S, Nielsen H, Foged C . Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release. 2009; 142(1):138-45. PMC: 7126878. DOI: 10.1016/j.jconrel.2009.10.010. View

11.

Suarez S, OHara P, Kazantseva M, Newcomer C, Hopfer R, McMurray D . Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001; 48(3):431-4. DOI: 10.1093/jac/48.3.431. View

12.

Misra A, Hickey A, Rossi C, Borchard G, Terada H, Makino K . Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb). 2010; 91(1):71-81. DOI: 10.1016/j.tube.2010.08.009. View

13.

Shive , Anderson . Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 2000; 28(1):5-24. DOI: 10.1016/s0169-409x(97)00048-3. View

14.

Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma G . Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release. 2009; 142(3):339-46. DOI: 10.1016/j.jconrel.2009.11.020. View

15.

Telko M, Hickey A . Dry powder inhaler formulation. Respir Care. 2005; 50(9):1209-27. View

16.

Pandey R, Sharma A, Zahoor A, Sharma S, Khuller G, Prasad B . Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003; 52(6):981-6. DOI: 10.1093/jac/dkg477. View

17.

MCCONVILLE J, Patel N, Ditchburn N, Tobyn M, Staniforth J, Woodcock P . Use of a novel modified TSI for the evaluation of controlled-release aerosol formulations. I. Drug Dev Ind Pharm. 2000; 26(11):1191-8. DOI: 10.1081/ddc-100100991. View

18.

Sung J, Padilla D, Garcia-Contreras L, Verberkmoes J, Durbin D, Peloquin C . Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009; 26(8):1847-55. PMC: 10247220. DOI: 10.1007/s11095-009-9894-2. View

19.

Sharma R, Saxena D, Dwivedi A, Misra A . Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res. 2001; 18(10):1405-10. DOI: 10.1023/a:1012296604685. View

20.

Chew N, Shekunov B, Tong H, Chow A, Savage C, Wu J . Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci. 2005; 94(10):2289-300. DOI: 10.1002/jps.20426. View